Igor Puzanov Roswell Park Comprehensive Cancer Center Jacobs School of Medicine, University at Buffalo
Present and future of immunotherapy in melanoma
First line choice in melanoma: immunotherapy or target therapy? We asked Omid Hamid, Director of Melanoma Therapeutics of The Angeles Clinic and Research Institute of Santa Monica. And what about monotherapy? In which patients we could use this therapeutical approach? From the Immunotherapy & Melanoma Bridge 2017 held in Naples.